Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
B-cell Acute Lymphoblastic Leukemia (B-ALL)
100%
Ph-like
100%
Combination Strategy
100%
Tyrosine Kinase Inhibitor
53%
Leukemia
33%
Bone Marrow
20%
Xenograft Model
13%
Acute Lymphoblastic Leukemia Cells
13%
MTOR Inhibitor
13%
Xenograft
13%
High Risk
13%
Ph-negative
13%
Specific Aims
13%
Leukemia Cells
6%
BCR/ABL Fusion Gene
6%
Clinical Testing
6%
Philadelphia Chromosome
6%
Bone Marrow Cells
6%
Older Adults
6%
Single Treatment
6%
Response to Therapy
6%
EGFR-TKI Resistance
6%
Mammalian Target of Rapamycin (mTOR)
6%
Phosphoflow
6%
Genetic Lesions
6%
Multiparametric Analysis
6%
Intrinsic Resistance
6%
Preadolescent children
6%
Xenografted Mice
6%
Cure Rate
6%
CyTOF
6%
Cell Population
6%
ATP-competitive Inhibitors
6%
Gene Expression
6%
BCR-ABL Inhibitors
6%
Tyrosine Kinase
6%
Clinical Trials
6%
Combination Treatment
6%
Gene Activation
6%
Rapamycin
6%
Patient-specific
6%
Normal Bone Marrow
6%
Case-driven
6%
Well Tolerated
6%
Dual Pathway Inhibition
6%
Therapeutic Dose
6%
Abl Tyrosine Kinase
6%
Similar Genes
6%
High-risk Population
6%
Tyrosine Kinase Inhibitor Treatment
6%
Tumor
6%
Survival Signaling
6%
Kinase Signaling
6%
Cycling Cells
6%
Phosphoproteomics
6%
Survival Mechanisms
6%
Young Adult Patients
6%
Medicine and Dentistry
Acute B-Cell Lymphoblastic Leukemia
100%
Tyrosine-Kinase Inhibitor
76%
Leukemia
38%
Xenograft
30%
Leukemia Cell
23%
B Cell
15%
Acute Lymphoblastic Leukemia
15%
Protein Tyrosine Kinase
15%
Mammalian Target of Rapamycin Inhibitor
15%
Adolescence
15%
Philadelphia 1 Chromosome
7%
Adenosine Triphosphate
7%
Gene Activation
7%
High Risk Population
7%
Gene Expression
7%
Competitive Inhibition
7%
Phosphoproteome
7%
Cell Population
7%
Clinical Trial
7%
Phosphotransferase Inhibitor
7%
In Vitro
7%
Rapamycin
7%
Mammalian Target of Rapamycin
7%
Biological Marker
7%
Diseases
7%
Bone Marrow Cell
7%
Oncogene
7%
Cancer
7%
Kinase Signaling
7%
Tumor
7%
Genetics
7%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Tyrosine Kinase Inhibitor
66%
Mechanistic Target of Rapamycin
13%
Adolescence
13%
Phosphotransferase
13%
Kinase
13%
Phosphoproteome
6%
Competitive Inhibition
6%
Tyrosine
6%
Clinical Trial
6%
Gene Activation
6%
Tyrosine Kinase
6%
Oncogene
6%
Philadelphia Chromosome
6%
Adenosine Triphosphate
6%
Genomics
6%
Mammalian Target of Rapamycin
6%
Gene Expression
6%
Receptor Tyrosine Kinase
6%
High Risk Population
6%